Burzynski Research Institute (BZYR) Net Cash Flow (2010 - 2025)
Burzynski Research Institute (BZYR) posted Net Cash Flow of $1234.0 for Q4 2025, up 1021.82% sequentially from $110.0 in Q3 2025, and up 304.64% YoY from $304.96 in Q4 2024.
Burzynski Research Institute (BZYR) Net Cash Flow (2010 - 2025) Analysis & Trends
Burzynski Research Institute has reported Net Cash Flow for 16 years, with the latest figure at $1234.0 in Q4 2025.
- Quarterly Net Cash Flow rose 304.64% year-over-year to $1234.0 in Q4 2025, while the trailing twelve-month figure through Nov 2025 was $1552.0 (up 617.33% YoY) and the FY2025 annual result came in at -$463.0, down 223.14% from the prior year.
- Net Cash Flow improved to $1234.0 in Q4 2025 per BZYR's latest filing, from $110.0 in the prior quarter.
- Over five years, Net Cash Flow peaked at $4862.0 in Q4 2021 and troughed at -$3500.0 in Q3 2022.
- A 5-year average of $54.8 and a median of $172.0 in 2025 frame the typical range for Net Cash Flow.
- The widest YoY moves for Net Cash Flow: up 857.32% in 2021, down 1636.21% in 2021.
- Over 5 years, Net Cash Flow stood at $4862.0 in 2021, then slumped by 91.24% to $426.0 in 2022, then tumbled by 213.62% to -$484.0 in 2023, then fell by 24.59% to -$603.0 in 2024, then soared by 304.64% to $1234.0 in 2025.
- According to Business Quant data, Net Cash Flow over the past three periods registered $1234.0, $110.0, and -$26.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Burzynski Research Institute | 1.31 Mn | 1.31 Mn | - | 1,234.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Nov 30, 2025 | 1,234.00 |
| Nov 30, 2025 | 1,234.00 |
| Aug 31, 2025 | 110.00 |
| Aug 31, 2025 | 110.00 |
| May 31, 2025 | -26.00 |
| May 31, 2025 | -26.00 |
| Feb 28, 2025 | 234.00 |
| Feb 28, 2025 | 234.00 |
| Nov 30, 2024 | -603.00 |
| Nov 30, 2024 | -603.00 |
| Aug 31, 2024 | 919.00 |
| Aug 31, 2024 | 919.00 |
| May 31, 2024 | -1,013.00 |
| May 31, 2024 | -1,013.00 |
| Feb 29, 2024 | 397.00 |
| Feb 29, 2024 | 397.00 |
| Nov 30, 2023 | -484.00 |
| Nov 30, 2023 | -484.00 |
| Aug 31, 2023 | 1,249.00 |
| Aug 31, 2023 | 1,249.00 |